Europe Peanut Allergy Treatment Market Size & Outlook
Related Markets
Europe peanut allergy treatment market highlights
- The Europe peanut allergy treatment market generated a revenue of USD 145.7 million in 2023.
- The market is expected to grow at a CAGR of 10.6% from 2024 to 2030.
- In terms of segment, epinephrine was the largest revenue generating drug class in 2023.
- Immunotherapies is the most lucrative drug class segment registering the fastest growth during the forecast period.
- Country-wise, Italy is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 145.7 million |
| Market revenue in 2030 | USD 295.7 million |
| Growth rate | 10.6% (CAGR from 2023 to 2030) |
| Largest segment | Epinephrine |
| Fastest growing segment | Immunotherapies |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antihistamines, Epinephrine, Immunotherapies, Other Drug Class |
| Key market players worldwide | Nestle SA, Sanofi SA, DBV Technologies SA ADR, PureTech Health PLC, Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd ADR, Protagonist Therapeutics Inc, Aravax, Alladapt Immunotherapeutics |
Other key industry trends
- In terms of revenue, Europe region accounted for 30.5% of the global peanut allergy treatment market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 248.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Peanut Allergy Treatment Market Scope
Peanut Allergy Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Alladapt Immunotherapeutics | View profile | 11-50 | Menlo Park, California, United States, North America | https://www.alladapt.com/ |
| Aravax | View profile | 11-50 | Melbourne, Victoria, Australia, Oceania | http://www.aravax.com.au/ |
| Protagonist Therapeutics Inc | View profile | 124 | 7707 Gateway Boulevard, Suite 140, Newark, CA, United States, 94560 | https://www.protagonist-inc.com |
| PureTech Health PLC | View profile | 90 | 6 Tide Street, Suite 400, Boston, MA, United States, 02210 | https://www.puretechhealth.com |
| DBV Technologies SA ADR | View profile | 105 | 177-181 avenue Pierre Brossolette, Montrouge, France, 92120 | http://www.dbvtechnologies.com |
| Teva Pharmaceutical Industries Ltd ADR | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
| Regeneron Pharmaceuticals Inc | View profile | 13450 | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 | https://www.regeneron.com |
| Nestle SA | View profile | 270000 | Avenue Nestle 55, Vevey, Switzerland, CH-1800 | https://www.nestle.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
Europe peanut allergy treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peanut allergy treatment market will help companies and investors design strategic landscapes.
Epinephrine was the largest segment with a revenue share of 47.43% in 2023. Horizon Databook has segmented the Europe peanut allergy treatment market based on antihistamines, epinephrine, immunotherapies, other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
In Europe, a noteworthy development in peanut allergy treatment has emerged, with the NHS in England taking a significant step by introducing a treatment, Palforzia, in December 2021. This treatment was designed to help individuals build tolerance to peanuts, reducing the severity of symptoms, including potentially life-threatening anaphylaxis.
Over the last decade, the prevalence of peanut allergies among children in Western countries doubled, according to Allergy UK. The symptoms of peanut allergy can range from hives, swelling, and itching to stomach cramps, nausea, & throat tightening. Peanuts or traces of them can be found in a wide range of foods, from cereals to chocolates.
However, children and young people between the ages of 4 and 17 are now set to receive a novel treatment, allowing them to lead more normal lives without the constant fear of accidental peanut exposure. Clinical trials have shown significant improvements, and this initiative promises to have a positive impact on patients & their families.
Reasons to subscribe to Europe peanut allergy treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe peanut allergy treatment market databook
-
Our clientele includes a mix of peanut allergy treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe peanut allergy treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Europe peanut allergy treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe peanut allergy treatment market size, by country, 2018-2030 (US$M)
Europe Peanut Allergy Treatment Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
